Alexandra Oana ENACHE, Mihail MATEI, Lavinia Eugenia LIPAN, Oana Gabriela CRACIUN, Laura Diana ȘTEFAN, Andra Georgiana STOICA, Zsofia VARADY, Alina Daniela TANASE
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended in first complete remission (CR) for adverse and intermediate-risk acute myeloid leukemia (AML) and not recommended for AML patients with favourable disease. Allo-HSCT is standard of care in high-risk acute lymphoblastic leukaemia (ALL) and relapsed ALL but is not indicated for standard-risk ALL. Even though in many studies benefit for survival was proven for these patients, relapse rates (RR) at one year (32.9% for LAM and 34% for LAL) remains problematic. We want to report the outcomes of patients treated for acute leukaemia in our centre.